AstraZeneca PLC vs Johnson & Johnson
AZN vs JNJ — side-by-side comparison from reported financials. AZN leads 6, JNJ leads 5 of 11 comparable metrics.
AstraZeneca PLC
AZN · Healthcare
$159.20+0.26%Solid
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | AZN | JNJ |
|---|---|---|
| Price | $159.20 | $261.79 |
| Market cap | $247B | $631B |
| Revenue (TTM) | $58.7B | $97.9B |
| Revenue growth | +9.8% | +5.6% |
| Net margin | 17.4% | 21.5% |
| Free cash flow | $10.7B | $22.2B |
| Net cash (debt) | ($27.4B) | ($27.8B) |
| 1-year price return | -6.4% | +37.0% |
| P/E | 23.4 | 29.9 |
| P/E vs own history (cheap-side %) | 65% | 16% |
| Dividend yield | 2.01% | 2.00% |
| Return on equity | 22% | 26% |
| Altman Z-score | 2.16 | — |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 96,100 | 140,800 |
Full résumé-style profiles: AZN CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.